Our chRDNA genome-editing technology fuels innovation

Precision genome editing

Our next-generation Cas9 and Cas12a chRDNA (CRISPR hybrid RNA-DNA) precision genome-editing technology enables complex edits, including multiplexed gene insertions and knockouts, with a high degree of specificity and lower levels of off-target editing than first-generation CRISPR-Cas9.

chRDNA technology

chRDNA Technology Platform image

Off-the-shelf CAR-T cell therapies

CAR-T cell therapies have shown great promise in treating blood cancers. Our CAR-T cell therapies are armored for potentially improved antitumor activity and are designed to reach a broad number of patients with off-the-shelf treatment options.

CAR-T cell therapy platform

iPSC-derived CAR-NK platform

We believe NK cells are a promising cell type for disease treatment. We have developed robust protocols to edit iPSCs and to differentiate and expand them into NK cells.

CAR-NK platform

CAR-NK cell therapies image

Scientific publications

Recent publications

Improved genome editing with Cas12a and Cas9 chRDNA platform in T, NK, B, and iPS cells
Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®. February 21-24, 2024.

Conformational control of Cas endonucleases by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells
Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT). May 16, 2022.

chRNDA and CRISPR

Improved genome editing with Cas12a and Cas9 chRDNA platform in T, NK, B, and iPS cells
Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®. February 21-24, 2024.

Conformational control of Cas endonucleases by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells
Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT). May 16, 2022.

Advances in industrial biotechnology using CRISPR-Cas systems
Trends in Biotechnology. February 1, 2018.

CB-010

CB-011

CAR-NK

CB-020, an Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic CAR-NK Cell Therapy, Engineered for Enhanced Activity Against Solid Tumors
12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research – Translating Knowledge into Practice. December 10-14, 2022.